Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Affymax (AFFY) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,620
  • Shares Outstanding, K 37,490
  • Annual Sales, $ 1,370 K
  • Annual Income, $ -14,420 K
  • 36-Month Beta 1.90
  • Price/Sales N/A
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0650 +7.69%
on 11/29/16
0.0830 -15.66%
on 11/30/16
-0.0050 (-6.67%)
since 11/04/16
3-Month
0.0610 +14.75%
on 09/12/16
0.0950 -26.32%
on 09/08/16
-0.0250 (-26.32%)
since 09/02/16
52-Week
0.0500 +40.00%
on 08/17/16
0.1000 -30.00%
on 04/12/16
-0.0220 (-23.91%)
since 12/04/15

Most Recent Stories

More News
Illumina Inc. Reports Q4 Earnings Decline

Image source: Illumina. Things weren't looking great for Illumina as the second month of 2016 began. Shares of the genomic sequencing company were down 17% year to date. Investors were hoping for...

R. Scott Greer Joins Inogen Board of Directors

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that R. Scott Greer has been appointed as an independent...

Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog

Gilead Sciences, Inc.'s (GILD) fourth-quarter earnings (including stock-based compensation expenses) of $2.38 per share.

KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors

KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.

Affymax reports special cash distribution and new appointment

The board of directors of Affymax (Other OTC:AFFY), a biopharmaceutical company, on Thursday declared its special distribution of USD0.05 per share of its stock.

Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards

Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant...

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer

Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution...

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY

TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX") COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD").

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY

TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX") COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD").

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY

TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX") COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD").

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Support & Resistance

2nd Resistance Point 0.0820
1st Resistance Point 0.0760
Last Price 0.0700
1st Support Level 0.0670
2nd Support Level 0.0640

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.